<?xml version="1.0" encoding="UTF-8"?>
<p id="Par17">Tissues were biopsied and routinely paraffin-embedded. VEGFR2, PDGFR2 and C-Kit expression was examined by immunohistochemistry as detailed in Additional file 
 <xref rid="MOESM1" ref-type="media">1</xref>: Methods. Furthermore, blood samples were collected to determine plasma VEGF and PDGF and stem cell factor (SCF) levels at day 0 and 15 after famitinib therapy and 12Â weeks after completing CCRT (Additional file 
 <xref rid="MOESM1" ref-type="media">1</xref>: Methods). Plasma EBV DNA concentrations were routinely measured by quantitative PCR as we described previously [
 <xref ref-type="bibr" rid="CR39">39</xref>, 
 <xref ref-type="bibr" rid="CR40">40</xref>].
</p>
